Research blog - for professionals

Our Lead Consultant for CT, Dr Andrew Gogbashian, is one of the authors of an article published this month in “In Vivo”. The article discusses the short-term effects on quality of life when a chemotherapy treatment called Carboplatin AUC10 is used for stage 2/3 metastatic seminoma.

back to all news
Vicki Major
16 January, 2019

Our Lead Consultant for CT, Dr Andrew Gogbashian, is one of the authors of an article published this month in the journal In Vivo. The article discusses the short-term effects on quality of life when a chemotherapy treatment called Carboplatin AUC10 is used for stage 2/3 metastatic seminoma.  

Stage 2/3 metastatic seminoma is a type of testicular cancer, which has spread only to the lymph nodes giving a high chance of survival. Seminoma usually occurs in men between 25 to 55 years of age and accounts for 40-45% of testicular cancers.  

Nearly all men survive seminoma so the treatment they receive should be minimal giving a good chance of cure without many side effects. The article was a review of patients treated with Carboplatin AUC10 only over a 4-84 month timeframe.  

The researchers looked at hair loss, hearing impairment, days absent from work and low levels of a type of infecting fighting white blood cell called neutrophils. The article concluded that; “Carboplatin AUC10 is a safe and effective treatment for stage II/III seminoma with better health-related quality of life than experienced with combination cisplatin-based chemotherapy”.

  • For the full article, In Vivo (open access)
categories
2019
popular articles